TearScience’s Tim Willis to Speak on CEO Panel at CED Life Science Conference 2012

MORRISVILLE, N.C.,— February 13, 2012—TearScience, a venture funded medical device company, today announced that its CEO and co-founder, Tim Willis, will be participating in a CEO panel discussion at the 21st annual CED Life Science Conference, to be held February 15-16, 2012, at the Raleigh Convention Center. This session, entitled “How to Survive in 2012 and Beyond,” will help entrepreneurs understand the various ways to grow their business including private financing, venture capital funding, initial public offering, partnerships, bringing a new product to market, and mergers and acquisitions.

The panel will include:
• Vipin Garg Ph.D., CEO, Tranzyme Pharma as moderator
• David Levison, CEO, CardioDX
• Neal Fowler, CEO, Liquidia Technologies
• Mark A. Sirgo, Pharma.D., CEO, BioDelivery Sciences International, Inc.
• Tim Willis, CEO and co-founder, TearScience.

“I look forward to participating on this panel along with other leaders of thriving life science companies,” said Tim Willis. “I’m happy to share my experience on how to successfully bring a new breakthrough technology to market with aspiring entrepreneurs.”

TearScience provides a system that helps eye care physicians treat patients who suffer from evaporative dry eye. Evaporative dry eye occurs when meibomian glands in the eyelids become obstructed and do not secrete the oily lipids needed to keep the water portion of tears from evaporating too quickly. TearScience’s system includes two medical devices, the LipiView® Ocular Surface Interferometer and the LipiFlow® Thermal Pulsation System. LipiView® captures detailed digital images to allow physicians to assess a dry eye patient’s tear film while the LipiFlow® treats evaporative dry eye disease by unblocking obstructed meibomian glands located in the eyelids during a 12-minute in-office procedure. The goal of unblocking the glands is to allow them to resume their natural production of lipids needed for a healthy tear film.
“The CED Life Science Conference represents one of the largest annual gatherings of the life science community in the Southeast,” said Joan Siefert Rose, CED president. “We are proud to feature many of the Triangle’s best emerging life science companies during the Emerging Company Showcase and their CEOs on the CEO panel.”

Industry professionals may attend the conference by registering on-site at the Raleigh Convention Center on February 15 or 16. For a full conference agenda, visit

About TearScience, Inc.
Headquartered in Morrisville, North Carolina, TearScience has pioneered devices that provide significant clinical improvement in the treatment of evaporative dry eye. Of the more than 100 million dry eye sufferers worldwide, approximately 80 percent have evaporative dry eye, which is caused by meibomian gland dysfunction (MGD) and a lipid deficiency of the eye’s natural tear film. The Tear Film and Ocular Surface Society (TFOS) workshop, involving two years of work by 50 leading experts from around the world, concluded that MGD is an under-estimated condition and is very likely the most frequent cause of dry eye disease. Common symptoms of the disease include eye irritation, dryness, redness, tiredness, and visual disturbances. TearScience’s integrated, in-office system enables eye care professionals to effectively address a root cause of evaporative dry eye, obstructed meibomian glands. For additional information, visit

Media Contact:
Mary Hecht-Kissell
(919) 459-4803

Add a Comment

You must be logged in to post a comment.